Genetically predicted TWEAK mediates the association between lipidome and Keratinocyte Carcinomas
Skin Research and Technology · 2024
DOI: 10.1111/srt.13781 ↗Kurz gefasst
Fachartikel in der Zeitschrift Skin Research and Technology, 2024. Verfasst von Hao Lei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China. Hauptthemen laut MEDLINE: Skin Neoplasms, Cytokine TWEAK, Keratinocytes, Lipidomics. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Reports suggest that lipid profiles may be linked to the likelihood of developing skin cancer, yet the exact causal relationship is still unknown.
Objective
This study aimed to examine the connection between lipidome and skin cancers, as well as investigate any possible mediators.
Methods
A two‐sample Mendelian randomization (MR) analysis was conducted on 179 lipidomes and each skin cancer based on a genome‐wide association study (GWAS), including melanoma, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC). Then, Bayesian weighted MR was performed to verify the analysis results of two‐sample MR. Moreover, a two‐step MR was employed to investigate the impact of TNF‐like weak inducer of apoptosis (TWEAK)‐mediated lipidome on skin cancer rates.
Results
MR analysis identified higher genetically predicted phosphatidylcholine (PC) (17:0_18:2) could reduce the risk of skin tumors, including BCC (OR = 0.9149, 95% CI: 0.8667–0.9658), SCC (OR = 0.9343, 95% CI: 0.9087–0.9606) and melanoma (OR = 0.9982, 95% CI: 0.9966–0.9997). The proportion of PC (17:0_18:2) predicted by TWEAK‐mediated genetic prediction was 6.6 % in BCC and 7.6% in SCC. The causal relationship between PC (17:0_18:2) and melanoma was not mediated by TWEAK.
Conclusion
This study identified a negative causal relationship between PC (17:0_18:2) and keratinocyte carcinomas, a small part of which was mediated by TWEAK, and most of the remaining mediating factors are still unclear. Further research on other risk factors is needed in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.
- State Key Laboratory of Military Stomatology & National Clinical Research Center for Oral Diseases & Shaanxi Clinical Research Center for Oral Diseases, Department of Orthodontics, School of Stomatology, The Fourth Mili…
- Department of Dermatology, Tangdu Hospital, Air Force Military Medical University, Xi'an, Shaanxi Province, China.
- Department of Dermatology, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.
- The First Department of General Surgery, the Third Affiliated Hospital and Shaanxi Provincial People's Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.
ORCID-Profile: Hao Lei, Ruimin Bai, Ningyi Xian, Xiaolin Zhou
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Lei, H., Chen, X., Bai, R., Wang, Q., Xian, N., Zhao, X., Zhou, X., Zheng, Y., & Wang, G. (2024). Genetically predicted TWEAK mediates the association between lipidome and Keratinocyte Carcinomas. Skin Research and Technology. https://doi.org/10.1111/srt.13781
Vancouver
Lei H, Chen X, Bai R, Wang Q, Xian N, Zhao X, et al. Genetically predicted TWEAK mediates the association between lipidome and Keratinocyte Carcinomas. Skin Research and Technology. 2024. doi:10.1111/srt.13781
BibTeX
@article{Lei2024,
author = {Lei, Hao and Chen, Xin and Bai, Ruimin and Wang, Qian and Xian, Ningyi and Zhao, Xinrong and Zhou, Xiaolin and Zheng, Yan and Wang, Guorong},
title = {Genetically predicted TWEAK mediates the association between lipidome and Keratinocyte Carcinomas},
journal = {Skin Research and Technology},
year = {2024},
doi = {10.1111/srt.13781}
}
EUVIMED